ClinVar Miner

Submissions for variant NM_000137.4(FAH):c.1203C>G (p.Tyr401Ter)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003226638 SCV003922525 likely pathogenic Tyrosinemia type I 2023-03-18 criteria provided, single submitter clinical testing Variant summary: FAH c.1203C>G (p.Tyr401X) results in a premature termination codon and is predicted to cause a truncation of the encoded protein. Although the variant is not predicted to cause absence of the protein through nonsense mediated decay, the variant disrupts the last 19 amino acids in the protein sequence. Pathogenic missense variants downstream of this truncation have been reported in ClinVar (e.g. ClinVar: 459903), suggesting that the terminal 19 amino acids are important for normal function. The variant was absent in 251416 control chromosomes (gnomAD). To our knowledge, no occurrence of c.1203C>G in individuals affected with Tyrosinemia Type 1 and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Baylor Genetics RCV003226638 SCV004195908 likely pathogenic Tyrosinemia type I 2022-12-28 criteria provided, single submitter clinical testing
Invitae RCV003226638 SCV004479617 pathogenic Tyrosinemia type I 2023-04-13 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the FAH protein in which other variant(s) (p.Val412Glu) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with FAH-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Tyr401*) in the FAH gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 19 amino acid(s) of the FAH protein.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.